Has Cannabis Dronabinol Shown Cognitive Improvement in Dementia?

PostedMarch 12, 2026

UpdatedMarch 12, 2026

ByMy Patient Advice

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

Interest in whether dronabinol, a synthetic form of tetrahydrocannabinol (THC), can improve cognition in dementia has increased over the past few years. However, according to NHS and NICE guidance, there is currently no evidence that dronabinol or other cannabis-based medicines enhance memory, attention, or thinking abilities in people with dementia (NICE NG97; NICE NG144).

What The Research Shows

Dronabinol has been studied mainly for its potential to reduce agitation or behavioural symptoms, not to improve cognitive function. Clinical trials between 2023 and 2025 consistently report no measurable improvement in cognition compared with placebo.

A 2023 randomised, double-blind crossover trial in older adults with dementia found that dronabinol and similar cannabinoids did not significantly change memory or executive functioning, although minor reductions in agitation were observed (PubMed Study).

Further reviews and feasibility studies, including a Swiss 2024 trial protocol using THC/CBD oil, suggest cannabinoids may be well tolerated, but the cognitive outcomes remain neutral or uncertain (Swiss Study). Systematic reviews published in 2024–2025 reinforce this conclusion, noting that small sample sizes and short study durations make it difficult to identify real cognitive benefits (Meta-Analysis).

What Guidelines Say

According to NHS and NICE, cannabis-based medical products should not be used to treat dementia or its cognitive symptoms. Both organisations highlight the lack of robust clinical data and potential safety concerns, particularly in frail or cognitively impaired populations (NHS Guidance).

The Alzheimer’s Society UK also emphasises that there is no evidence to suggest cannabis or its derivatives can prevent or reverse cognitive decline in dementia (Alzheimer’s Society).

The Clinical Bottom Line

No clinical trial has demonstrated meaningful cognitive improvement from dronabinol in dementia.

Studies mainly show mild effects on agitation, not memory or thinking.

Evidence remains limited, small-scale, and short-term.

NICE and NHS do not recommend cannabinoids for cognitive symptoms of dementia.

Any use should only occur within regulated clinical research settings.

Educational Context: AlleviMed

Educational platforms such as AlleviMed provide reliable information about how medical cannabis eligibility is assessed in the UK. They clarify that licensed cannabis-based medicines are currently restricted to specific conditions such as severe epilepsy, chemotherapy-induced nausea, and spasticity in multiple sclerosis, dementia is not one of them.

Takeaway

Despite growing interest in dronabinol for dementia, no evidence supports cognitive improvement. NICE and NHS continue to advise against using cannabis-based medicines for dementia symptoms outside research settings. The best current approach focuses on established dementia care strategies, behavioural management, and medical supervision by qualified professionals.

Julia Sutton, MSc

Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Clarissa Morton, PharmD

Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.